Hemodynamic and functional assessment of patients with sickle cell disease and pulmonary hypertension.

RATIONALE Although pulmonary hypertension (PH) is a common complication of sickle cell disease (SCD) associated with high mortality, there exist few data characterizing hemodynamics and cardiopulmonary function in this population. OBJECTIVES To characterize hemodynamics and cardiopulmonary function in patients with SCD with and without PH. METHODS Patients with SCD with PH (n = 26) were compared with control subjects with SCD but without PH (n = 17), matched for age, hemoglobin levels, and fetal hemoglobin levels. MEASUREMENTS AND MAIN RESULTS Upon catheterization, 54% of the patients with PH had pulmonary arterial hypertension, and 46% had pulmonary venous hypertension. When compared with control subjects, patients with PH exhibited lower six-minute-walk distance (435 +/- 31 vs. 320 +/- 20 m, p = 0.002) and oxygen consumption (50 +/- 3% vs. 41 +/- 2% of predicted, p = 0.02), and also had mild restrictive lung disease and more perfusion abnormalities on radionuclide lung scans. The six-minute-walk distance in this population inversely correlated with tricuspid regurgitant jet velocity (r = -0.55, p < 0.001), and mean pulmonary artery pressure (r = -0.57, p < 0.001), and directly correlated with maximal oxygen consumption (r = 0.49, p = 0.004), even after adjustment for hemoglobin, supporting an independent contribution of increasing pulmonary artery pressures to loss of exercise capacity. CONCLUSIONS Patients with SCD-associated PH have both pulmonary arterial and venous PH associated with severe limitations in exercise capacity, likely compounded by interstitial lung fibrosis and severe anemia. These data support the use of the six-minute-walk distance as an index of PH and cardiopulmonary function in patients with SCD.

[1]  Dina Brooks,et al.  ATS statement on six-minute walk test. , 2003, American journal of respiratory and critical care medicine.

[2]  M. Hartikainen,et al.  Mitral valve replacement with ball and tilting disc valve prosthesis. A clinical and haemodynamic study. , 1976, Scandinavian journal of thoracic and cardiovascular surgery.

[3]  A. Dwyer,et al.  Hermansky-Pudlak syndrome: radiography and CT of the chest compared with pulmonary function tests and genetic studies. , 2002, AJR. American journal of roentgenology.

[4]  D. Haskard,et al.  Hemoglobin Scavenger Receptor CD163 Mediates Interleukin-10 Release and Heme Oxygenase-1 Synthesis: Antiinflammatory Monocyte-Macrophage Responses In Vitro, in Resolving Skin Blisters In Vivo, and After Cardiopulmonary Bypass Surgery , 2004, Circulation research.

[5]  A. Elami,et al.  Impaired oxygenation and increased hemolysis after cardiopulmonary bypass in patients with glucose-6-phosphate dehydrogenase deficiency. , 2003, The Annals of thoracic surgery.

[6]  K. Kerr,et al.  Successful pulmonary thromboendarterectomy in two patients with sickle cell disease. , 1998, American journal of respiratory and critical care medicine.

[7]  S. Rich,et al.  The effect of high doses of calcium-channel blockers on survival in primary pulmonary hypertension. , 1992, The New England journal of medicine.

[8]  Bruce Barton,et al.  N-terminal pro-brain natriuretic peptide levels and risk of death in sickle cell disease. , 2006, JAMA.

[9]  John L. Hankinson,et al.  Standardization of Spirometry, 1994 Update. American Thoracic Society. , 1995, American journal of respiratory and critical care medicine.

[10]  B. Zilberstein,et al.  Prevalence of pulmonary hypertension in patients with hepatosplenic Mansonic schistosomiasis--prospective study. , 2003, Hepato-gastroenterology.

[11]  M. Gladwin,et al.  Chronic sickle cell lung disease: new insights into the diagnosis, pathogenesis and treatment of pulmonary hypertension , 2005, British journal of haematology.

[12]  M. Gladwin,et al.  Pulmonary hypertension as a risk factor for death in patients with sickle cell disease. , 2004, The New England journal of medicine.

[13]  Y. Ohara,et al.  Hemolytic characteristics of a pivot bearing supported Gyro centrifugal pump (C1E3) simulating various clinical applications. , 1996, Artificial organs.

[14]  P. Adegboyega,et al.  Pulmonary hypertension in sickle cell hemoglobinopathy: a clinicopathologic study of 20 cases. , 2002, Human pathology.

[15]  O. Castro,et al.  Pulmonary hypertension in sickle cell disease: cardiac catheterization results and survival. , 2003, Blood.

[16]  E. Vichinsky Pulmonary hypertension in sickle cell disease. , 2004, The New England journal of medicine.

[17]  J. Krishnan,et al.  Pulmonary hypertension as a risk factor for death in patients with sickle cell disease. , 2004, The New England journal of medicine.

[18]  D. Farmakis,et al.  Cardiac involvement in thalassemia intermedia: a multicenter study. , 2001, Blood.

[19]  M. Gladwin,et al.  The clinical sequelae of intravascular hemolysis and extracellular plasma hemoglobin: a novel mechanism of human disease. , 2005, JAMA.

[20]  M. Hughson,et al.  Pulmonary thrombotic arteriopathy in patients with sickle cell disease. , 2001, Archives of pathology & laboratory medicine.

[21]  R. Dixon,et al.  Sitaxsentan therapy for pulmonary arterial hypertension. , 2004, American journal of respiratory and critical care medicine.

[22]  J. E. Hansen,et al.  Principles of Exercise Testing and Interpretation , 1994 .

[23]  G. Grillone,et al.  Haemolysis during cardiopulmonary bypass: how to reduce the free haemoglobin by managing the suctioned blood separately , 2001, Perfusion.

[24]  J. Hankinson,et al.  American Thoracic Society. Single-breath carbon monoxide diffusing capacity (transfer factor). Recommendations for a standard technique--1995 update. , 1995, American journal of respiratory and critical care medicine.

[25]  M. Gladwin,et al.  Pulmonary Hypertension in Sickle Cell Disease: Cardiopulmonary Evaluation and Response to Chronic Phosphodiesterase 5 Inhibitor Therapy. , 2004 .

[26]  E. Strauss,et al.  Systemic surgical shunts and splenomegaly as causes of haemolysis in portal hypertension in mansonic schistosomiasis. Evaluation through serum levels of haptoglobin, hemopexin and bilirubins. , 1986, Journal of hepatology.

[27]  Arvind K. Shah,et al.  Causes of death in sickle cell disease: an autopsy study , 2003, British journal of haematology.

[28]  A. Van Tosh,et al.  Quantitative assessment of pulmonary hypertension in patients with tricuspid regurgitation using continuous wave Doppler ultrasound. , 1985, Journal of the American College of Cardiology.

[29]  Stanley L Hazen,et al.  Dysregulated arginine metabolism, hemolysis-associated pulmonary hypertension, and mortality in sickle cell disease. , 2005, JAMA.

[30]  J. E. Hansen,et al.  Predicted values for clinical exercise testing. , 2015, The American review of respiratory disease.

[31]  H. Hellems,et al.  Hemodynamic Studies in Sickle Cell Anemia , 1954, Circulation.

[32]  L. Olson,et al.  Parenchymal scarring is associated with restrictive spirometric defects in patients with chronic thromboembolic pulmonary hypertension. , 1996, Chest.

[33]  J. E. Hansen,et al.  Pulmonary function in primary pulmonary hypertension. , 2003, Journal of the American College of Cardiology.

[34]  Bosentan therapy for pulmonary arterial hypertension. , 2002, The New England journal of medicine.

[35]  M. Gladwin,et al.  Diastolic dysfunction is an independent risk factor for death in patients with sickle cell disease. , 2005, Journal of the American College of Cardiology.

[36]  W. Travis,et al.  Maximal oxygen uptake and severity of disease in lymphangioleiomyomatosis. , 2003, American journal of respiratory and critical care medicine.

[37]  M. Gladwin,et al.  Pulmonary complications of sickle cell anemia. A need for increased recognition, treatment, and research. , 2001, American journal of respiratory and critical care medicine.

[38]  S. Roy,et al.  Hemodynamic Effects of Chronic Severe Anemia , 1963, Circulation.

[39]  Paul Sorajja,et al.  Relationship of pulmonary arterial capacitance and mortality in idiopathic pulmonary arterial hypertension. , 2006, Journal of the American College of Cardiology.

[40]  G. Venn,et al.  A clinical evaluation of platelet function, haemolysis and oxygen transfer during cardiopulmonary bypass comparing the Quantum HF-6700 to the HF-5700 hollow fibre membrane oxygenator , 2000, Perfusion.